Moderna, Inc. (ETR:0QF)
Germany
· Delayed Price · Currency is EUR | Market Cap | 9.10B |
| Revenue (ttm) | 2.94B |
| Net Income (ttm) | -3.11B |
| Shares Out | n/a |
| EPS (ttm) | -8.07 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 70 |
| Average Volume | 548 |
| Open | 23.50 |
| Previous Close | 22.77 |
| Day's Range | 23.24 - 23.95 |
| 52-Week Range | 20.18 - 115.84 |
| Beta | 1.86 |
| RSI | 50.87 |
| Earnings Date | Jul 31, 2025 |
About Moderna
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, su... [Read more]
Financial Performance
In 2024, Moderna's revenue was $3.24 billion, a decrease of -52.75% compared to the previous year's $6.85 billion. Losses were -$3.56 billion, -24.46% less than in 2023.
Financial numbers in USD Financial StatementsNews
US stocks threatens to close at record levels but closes just off record levels
The broader stock indices threatened to close at record levels with the S&P index getting within one point of a record high level. The comes in at 6147.43. The high price today reached 6146.52. The NA...
Major US stocks close mixed. Dow is lower. S&P near unchanged. NASDAQ marginally higher
The major US stock indices closed the day with mixed results following the FOMC decision to keep rates unchanged, as widely expected. The Dow Jones Industrial Average slipped modestly, while the S&P 5...
Moderna's Options: A Look at What the Big Money is Thinking
Deep-pocketed investors have adopted a bearish approach towards Moderna (NASDAQ: MRNA), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled...
AI Meets Oncology: Caris Life Sciences' $5.35B IPO Tests Investor Appetite for Precision Medicine
Caris Life Sciences , an AI-driven precision oncology company, is targeting a $5.35 billion valuation in its U.S. initial public offering, aiming to raise up to $423.5 million. The Irving, Texas-based...
Moderna, Inc. (MRNA) Presents at Barclays Speaking the Science Call Series Transcript
US experts fear all vaccines at risk as Trump officials target mRNA jabs
Administration’s actions signal move away from technology as health agencies see vaccine-related shakeups As top US health officials turn against some mRNA vaccines, experts fear for the country’s pre...
FDA approves expanded use of Moderna's RSV shot, but uncertainty remains
The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include individuals 18-59 years of age who are at increased risk for severe illness from respirat...
FDA approves expanded use of Modernas RSV shot, but uncertainty remains
The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to 59 years old who are at increased risk for severe illness from respiratory s...
Moderna under pressure despite RSV vaccine approval into wider age group
Short bets on S&P 500 Healthcare sector ease in May; MRNA stays most shorted stock
Moderna falls on fears new CDC vaccine advisory panel could cloud RSV shot prospects
Moderna's shares fell 2.5% before the bell on Friday, on concerns whether a new CDC advisory panel would back the use of the company's respiratory syncytial virus vaccine in a broader age group.
FDA expands Moderna's RSV vaccine approval to at-risk adults
US FDA approves expanded use of Moderna's RSV vaccine for at-risk adults
The U.S. Food and Drug Administration on Thursday expanded the use of Moderna's respiratory syncytial virus vaccine to a lower group of high-risk adults aged 18 to 59 years.
Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease
Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS Newswire / June 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the ...
Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease
Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS Newswire / June 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the ...
BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal
BioNTech SE (NASDAQ: BNTX) on Thursday agreed to acquire CureVac N.V. (NASDAQ: CVAC) in an all-stock transaction . According to the agreement, shareholders can exchange CureVac shares for around $5....
Is it Time to Dump Your Shares of Moderna?
Moderna, Inc. (MRNA) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
Moderna to Present at Upcoming Barclays Speaking the Science Call Series on June 16, 2025
CAMBRIDGE, MA / ACCESS Newswire / June 11, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor event:Barclays Speaking the Science Call Series, on ...
20 stocks you should avoid — no matter how well the market does
These hard-to-short stocks are likely to lose money, researchers found.
Moderna to Present at Upcoming Barclays Speaking the Science Call Series on June 16, 2025
CAMBRIDGE, MA / ACCESS Newswire / June 11, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor event: Barclays Speaking the Science Call Series, on...
RFK Jr.'s firing of CDC vaccine advisors 'circumvents science' and could threaten public health, experts say
Health and Human Services Secretary Robert F. Kennedy Jr. has gutted a key government panel of vaccine advisors, a stunning move that some public health experts say undermines science, disrupts a trus...
Vaccine actions and policy positions under US Health Secretary Kennedy
U.S. Health Secretary Robert F. Kennedy Jr., a long-time vaccine skeptic, has been making sweeping changes to reshape U.S. regulation of vaccines, food and medicine.
Vaccine stocks muted as Wall Street takes 'wait and watch' approach after Kennedy's shake-up
Shares of global vaccine makers were muted on Tuesday as investors and analysts took a "wait and watch" approach after U.S. Health Secretary Robert F. Kennedy Jr. fired all members of an expert vaccin...
Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors.
Investors will be waiting for news on how the makeup of a reconstituted ACIP will look like.